QUINCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 USD | +2.91% |
|
+0.95% | +0.95% |
| 04-01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-26 | Transcript : Quince Therapeutics, Inc. - Special Call |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M 3.6B |
|---|---|---|---|---|---|
| Net income 2022 | -51M -4.08B | Net income 2023 | -31M -2.48B | EV / Sales 2022 | - |
| Net cash position 2022 | 89.73M 7.18B | Net cash position 2023 | 61.24M 4.9B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quince Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.91% | ||
| 1 week | +0.95% | ||
| 1 month | -6.19% | ||
| 3 months | -15.87% | ||
| 6 months | +4.95% | ||
| Current year | +0.95% |
1 week
0.98
1.12
1 month
0.891.14
Current year
0.891.43
1 year
0.841.74
3 years
0.54121.98
5 years
0.54121.98
10 years
0.54121.98
| Managers | Title | Age | Since |
|---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 18/05/22 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 30/04/22 |
Charles Ryan
PSD | President | 60 | 31/08/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 28/02/18 |
Luca Benatti
BRD | Director/Board Member | 63 | 22/10/23 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 18/05/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.06 | +2.91% | 120,833 |
| 25/04/24 | 1.03 | -2.83% | 93,060 |
| 24/04/24 | 1.06 | -4.50% | 91,171 |
| 23/04/24 | 1.11 | +4.72% | 129,361 |
| 22/04/24 | 1.06 | +0.95% | 57,652 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. The Companyâs asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patientâs own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.95% | 45.81M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- QNCX Stock
